ophthalmologytimes2h
Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children
Zhaoke Ophthalmology Limited is responsible for developing and obtaining regulatory approval for NVK-002 in Greater China, ...
ophthalmologytimes22h
Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System
Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient ...